NCT06487975 is a clinical trial investigating the effects of Bacillus Subtilis supplementation on Parkinson's disease (PD) biomarkers. Sponsored by the University of Edinburgh, this trial represents a growing interest in gut-brain axis therapies for neurodegenerative diseases. The study evaluates how modulation of the gut microbiome through probiotic supplementation may affect disease progression and biomarker profiles in PD patients. [@university]
This trial is part of a broader movement toward microbiome-based therapeutics in neurology, recognizing that the gut-brain axis plays a critical role in neurodegenerative processes. The rationale stems from observations that PD patients often exhibit gut dysfunction years before motor symptoms appear, suggesting that the microbiome may be both a therapeutic target and a source of disease biomarkers. [@braak2003]
The gut-brain axis is a bidirectional communication network linking the central nervous system with the enteric nervous system. This connection involves neural, hormonal, and immunological pathways that allow gut microorganisms to influence brain function and behavior. In Parkinson's disease, this axis has emerged as a key player in disease pathogenesis and progression.
NCT06487975 is a clinical trial investigating the effects of Bacillus Subtilis supplementation on Parkinson's disease (PD) biomarkers. Sponsored by the University of Edinburgh, this trial represents a growing interest in gut-brain axis therapies for neurodegenerative diseases. The study evaluates how modulation of the gut microbiome through probiotic supplementation may affect disease progression and biomarker profiles in PD patients. [@university]
This trial is part of a broader movement toward microbiome-based therapeutics in neurology, recognizing that the gut-brain axis plays a critical role in neurodegenerative processes. The rationale stems from observations that PD patients often exhibit gut dysfunction years before motor symptoms appear, suggesting that the microbiome may be both a therapeutic target and a source of disease biomarkers. [@braak2003]
The gut-brain axis is a bidirectional communication network linking the central nervous system with the enteric nervous system. This connection involves neural, hormonal, and immunological pathways that allow gut microorganisms to influence brain function and behavior. In Parkinson's disease, this axis has emerged as a key player in disease pathogenesis and progression.
The enteric nervous system (ENS), often called the "second brain," contains millions of neurons that line the gastrointestinal tract. Research has demonstrated that alpha-synuclein pathology can originate in the gut and propagate to the brain via the vagus nerve. This "body-first" hypothesis of PD pathogenesis suggests that misfolded alpha-synuclein initially forms in the gut and then travels retrogradely through vagal nerve fibers to the dorsal motor nucleus of the vagus and eventually to the substantia nigra. [@sampson2016]
Multiple clinical observations support the gut-brain connection in PD:
Bacillus subtilis is a Gram-positive, spore-forming bacterium that has been used safely as a probiotic for decades. Its spore-forming ability allows it to survive the harsh acidic environment of the stomach and reach the intestines viable. Once in the gut, B. subtilis spores germinate and colonize the intestinal mucosa, exerting beneficial effects through multiple mechanisms.
Key properties of Bacillus subtilis as a probiotic include:
One of the primary mechanisms through which Bacillus subtilis may benefit Parkinson's disease patients is the production of short-chain fatty acids (SCFAs). These molecules, including butyrate, propionate, and acetate, are produced by bacterial fermentation of dietary fiber and serve as crucial energy sources for colonocytes and signaling molecules throughout the body.
Butyrate is particularly important for gut and brain health:
In Parkinson's disease, neuroinflammation plays a critical role in dopaminergic neuron degeneration. SCFAs, particularly butyrate, have demonstrated anti-inflammatory effects in preclinical models:
Preclinical research suggests that Bacillus subtilis may directly affect alpha-synuclein aggregation and toxicity:
The primary objective of NCT06487975 is to evaluate the safety and efficacy of Bacillus subtilis supplementation on:
Inclusion criteria typically include:
Participants receive:
| Biomarker | Significance |
|-----------|-------------|
| Microbiome diversity (Shannon index) | Overall gut health |
| SCFA concentrations | Butyrate, propionate, acetate |
| Tight junction proteins | Gut barrier integrity |
| LPS levels | Systemic inflammation |
| Biomarker | Relevance |
|-----------|-----------|
| IL-6 | Pro-inflammatory cytokine |
| TNF-α | Neuroinflammation marker |
| IL-1β | Inflammatory response |
| CRP | Systemic inflammation |
| IL-10 | Anti-inflammatory cytokine |
| Biomarker | Description |
|-----------|-------------|
| Alpha-synuclein in CSF | Disease progression marker |
| Neurofilament light chain (NfL) | Neurodegeneration marker |
| Tau and p-tau | Alzheimer comorbidity |
This trial builds on a growing body of evidence linking gut microbiome dysbiosis to neurodegenerative diseases. The Microbiome page provides comprehensive information about the trillions of microorganisms inhabiting the human gastrointestinal tract and their effects on systemic health.
The gut-brain axis also plays a role in Alzheimer's disease (AD), where microbiome changes are associated with amyloid deposition and cognitive decline. Similar probiotic interventions are being explored for AD patients.
The vagus nerve serves as the primary neural conduit between the gut and brain. Alpha-synuclein may travel along this nerve in a prion-like fashion, spreading pathology from the enteric nervous system to the central nervous system.
If successful, Bacillus subtilis supplementation could offer:
Several challenges face microbiome-based PD therapies:
Several other trials are investigating microbiome modulation in PD:
| Trial | Intervention | Status |
|-------|-------------|--------|
| NCT03015311 | Fecal microbiota transplant | Recruiting |
| NCT04251468 | Probiotic blend | Completed |
| NCT04519294 | Synbiotic | Active |
Animal models have provided the rationale for human trials:
The following diagram shows the key molecular relationships involving NCT06487975: Bacillus Subtilis Gut Microbiome Intervention for PD discovered through SciDEX knowledge graph analysis: